Literature DB >> 2147942

Role of histamine in natural killer cell-mediated resistance against tumor cells.

K Hellstrand1, A Asea, S Hermodsson.   

Abstract

The formation of lung metastases by i.v.-injected B16 melanoma (F1 and F10 strain) cells in Swiss albino, C57BL/6, and BALB/c mice was reduced by a single dose of histamine given 24 h before tumor cell inoculation. The antimetastatic effect of histamine was specifically mediated by histamine H2-receptors (H2R): it was blocked by the H2R antagonist ranitidine and mimicked by dimaprit, a specific H2R agonist but not by an H2R-inactive structural analog of this compound, nor-dimaprit, or the H1R agonist 2-thiazolyl-ethylamide. A single dose of any of the H2R antagonists ranitidine, tiotidine, famotidine, or cimetidine drastically augmented metastasis. Effects of H2R-interactive compounds on B16 metastasis required intact NK cells, as judged by the inability of histamine or ranitidine to affect B16 metastasis after NK cell depletion in vivo using antibodies to asialo-GM1. NK-cell-mediated lysis of YAC-1 lymphoma cells in vivo was enhanced by histamine and reduced by ranitidine within 4 h after inoculation of tumor cells. The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone. The presented data are suggestive of an earlier unrecognized role for histamine in NK cell-mediated resistance against metastatic tumor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147942

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Up-regulation of histidine decarboxylase expression and histamine content in B16F10 murine melanoma cells.

Authors:  Steven C Davis; Sheena Clark; J Robert Hayes; Todd L Green; Carl A Gruetter
Journal:  Inflamm Res       Date:  2010-07-18       Impact factor: 4.575

Review 2.  Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perspectives.

Authors:  W M Purcell; C K Atterwill
Journal:  Neurochem Res       Date:  1995-05       Impact factor: 3.996

Review 3.  Histamine dihydrochloride: in the management of acute myeloid leukaemia.

Authors:  Lily P H Yang; Caroline M Perry
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

Review 4.  Spotlight on histamine dihydrochloride in acute myeloid leukaemia.

Authors:  Lily P H Yang; Caroline M Perry
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

Review 5.  Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

Authors:  K Hellstrand; M Brune; C Dahlgren; M Hansson; S Hermodsson; P Lindnér; U H Mellqvist; P Naredi
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

Review 6.  The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1996-09       Impact factor: 6.968

Review 7.  Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

8.  5-Propyl-2-deoxyuridine induced interference with glycosylation in herpes simplex virus infected cells. Nature of PdU-induced modifications of N-linked glycans.

Authors:  S Olofsson; I Sjöblom; K Hellstrand; D Shugar; C Clairmont; C Hirschberg
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Role of histamine in natural killer cell-dependent protection against herpes simplex virus type 2 infection in mice.

Authors:  K Hellstrand; A Asea; S Hermodsson
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

10.  Histamine in immunotherapy of advanced melanoma: a pilot study.

Authors:  K Hellstrand; P Naredi; P Lindner; K Lundholm; C M Rudenstam; S Hermodsson; M Asztély; L Hafström
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.